ReviewFrontiers in immunology2015
Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects.
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Clinical presentation and immunological features of Post-Malaria Neurologic Syndrome: a case report and review of literature.Malaria journal · 2020Pooled it
- Pentaglobin (immunoglobulin M-enriched immunoglobulin) as adjuvant therapy for premature and very low-birth-weight neonates with sepsis.Indian journal of pharmacologyTrial
- Unknown Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis: A New Mechanism of Action Beyond IgG Reduction.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Use of Immunoglobulin Replacement Therapy in Clinical Practice: A Review.Journal of immunotherapy and precision oncology · 2025Review
- Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG).PLoS neglected tropical diseases · 2024Article
- The use of intravenous immunoglobulin in intensive care.BJA education · 2024Review
- B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies.Rheumatology (Oxford, England) · 2023Article
- Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients.Transplantation direct · 2023Article
- Abrogation of neutrophil inflammatory pathways and potential reduction of neutrophil-related factors in COVID-19 by intravenous immunoglobulin.Frontiers in immunology · 2022Article
- Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system.Frontiers in immunology · 2022Article
- Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia.Scientific reports · 2021Article
- Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections.Microorganisms · 2021Review
- IVIg-induced plasmablasts in patients with Guillain-Barré syndrome.Annals of clinical and translational neurology · 2019Article
- Anti-inflammatory intravenous immunoglobulin (IVIg) suppresses homeostatic proliferation of B cells.Cytotechnology · 2018Article
- Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.PloS one · 2017Observational
- [Immunomodulatory therapy of autoimmune diseases : Quo vadis?].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2016Review
- Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.Frontiers in immunology · 2016Review
- Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.World journal of hepatology · 2015Review
- Editorial: Immunoglobulin Therapy in the 21st Century - the Dark Side of the Moon.Frontiers in immunology · 2015Article
- The effect of polyclonal and monoclonal based antibodies as promising potential therapy for treatment of sepsis: A systematic review.New microbes and new infectionsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous immunoglobulin (IVIG) is used as replacement therapy in patients with antibody deficiencies and at higher dosages in immune-mediated disorders. Although different mechanisms have been described in vitro, the in vivo immunomodulatory effects of IVIG are poorly understood. Different studies have suggested that IVIG modulates B-cell functions as activation, proliferation, and apoptosis. Recently, it was shown that IVIG induces in vitro B-cell unresponsiveness similar to anergy. In accord with this, we recently reported that IVIG therapy in patients affected by common variable immunodeficiency (CVID) interferes in vivo with the B-cell receptor (BCR) signaling by increasing constitutive ERK activation and by reducing the phosphorylated ERK increment induced by BCR cross-linking. Moreover, we observed that IVIG induces in CVID patients an increase of circulating CD21(low) B-cells, an unusual population of anergic-like B-cells prone to apoptosis. Therefore, IVIG at replacement dose in vivo could prime B-cells to an anergic, apoptotic program. Here, we discuss these recent findings, which may improve our understanding of the immunomodulatory effects of IVIG, individualizing single involved molecules for more specific treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.